Nuvation Bio (NUVB) Chief Executive David Hung said Sunday the latest results from two phase 2 studies evaluating Ibtrozi as a treatment for certain adults with non-small cell lung cancer showed "impressive" progression-free survival and durability of response.

The results also demonstrated "a tolerable and manageable safety profile that helps patients stay on therapy," Hung said.

One study showed a confirmed objective response rate of 85.2% at a median follow-up of 20.5 months, the company said.

Another study of 103 patients showed median progression-free survival of 44.6 months, the company said. In a cohort of the study with pretreated patients, the overall response rate was 51.5% at a median follow-up of 35.1 months.

Shares of Nuvation Bio gained more than 11% in premarket activity Monday.